Bellus Health gets new $4.10 price target at Mackie Research Capital

Jul 16 21:07 2019 Print This Article

Recent shifts in the competitive landscape have Mackie Research Capital analyst André Uddin raising his price target on Bellus Health (Bellus Health News, Stock Quote, Chart TSX:BLU). Uddin says in the landscape of chronic cough treatments, P2X3 inhibitors are showing the most promise and advanced class. “Four classes of treatments have been tested for chronic […]

The post Bellus Health gets new $4.10 price target at Mackie Research Capital appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

Canopy Growth will remain a problem for Constellation Brands, this investor says

The write-downs likely aren’t done yet. That’s the takeaway from portfolio manager Jason Mann’s assessment of Constellation Brands (Constellation Brands Stock Quote, Chart, News NYSE:STZ) and its troubled investment in cannabis company Canopy Growth (Canopy Growth Stock Quote, Chart, News TSX ...

The worst is over for Organigram, says Raymond James

Operational excellence was the takeaway from Organigram Holdings (Organigram Holdings Stock Quote, Chart, News TSX:OGI) in its latest quarter, according to Raymond James analyst Rahul Sarugaser, who in an update to clients on Wednesday raised his rating for OGI from “Market Perform 3” to “Out ...

PI Financial cuts price target on Aphria

Following the company’s second quarter results, PI Financial analyst Jason Zandberg has cut his price target on Aphria (Aphria Stock Quote, Chart, News TSX:APHA), though the analyst has maintained his “Buy” rating on the stock. On Tuesday, Aphria reported its Q2, 2020 results. The company los ...

Acasti Pharma placed under review by Mackie Research Capital

Disappointing results for its lead product candidate CaPre have led Mackie research capital analyst André Uddin to place Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) under review. This morning, Acasti reported topline results for Trilogy 1 Phase Three trail of CaPre that saw th ...

10 pot stocks that actually went up in 2019

2019 was, to say it mildly, not a good for Canada’s cannabis sector. The feel good story that was Canada’s leadership role in the space turned into a horror show. Just about every name brand in the sector took double-digit losses? Canopy Growth? Down 27 per cent. CannTrust? Down 76 per cent. Or ...

Profound Medical has 189% upside in 2020, Echelon says

Following a progress update on its TULSA-PRO device, Echelon Wealth Partners analyst Doug Loe has maintained his bullish target on Profound Medical (Profound Medical Stock Quote, Chart, News TSX:PRN). This morning, Profound announced it signed its first-ever U.S. multisite imaging centre agreement ...

Acasti Pharma keeps “Top Pick” Status at Echelon for 2020

Quebec-based omega-3 drug developer Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) is keeping its “Top Pick” status from Echelon Wealth Partners analyst Douglas Loe. In a research update to clients Tuesday, Loe maintained his “Speculative Buy” rating and $4.00 price target ...

Canopy Growth won’t be part of the pot sector carnage, this investor says

Want a potential winner in the cannabis sector? Keep your eyes on Canopy Growth (Canopy Growth Stock Quote, Chart, News TSX:WEED). Greg Taylor, chief investment officer at Purpose Investments, thinks that while many of Canada’s pot companies will fold as the industry goes through a major downsizi ...

Biotech stocks are ready to roar, this fund manager says

There’s good value to be had in 2020 from biotech stocks, says Eden Rahim of Next Edge Capital, who thinks that, in particular, Montreal-based Theratechnologies (Theratechnologies Stock Quote, Chart, News TSX:TH) is looking ready to break out. Biotech was a hot performer over the past decade as d ...

Canopy Growth Corp will survive, says James Hodgins

Panning for gold among the rubble of Canada’s blown-apart pot sector? That’s hazardous work, says investor James Hodgins of Curvature Hedge Strategies, but if you’re bound and determined, sticking with a name like Canopy Growth Corp. (Canopy Growth Corp. Stock Quote, Chart, News TSX:WEED) mig ...